Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome
A Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of 40mg/Day KW-6002 (Istradefylline) in Subjects With Restless Legs Syndrome
Sponsor: Kyowa Kirin Co., Ltd.
This PHASE2 trial investigates Restless Legs Syndrome and Sleep Disorder and is currently completed. Kyowa Kirin Co., Ltd. leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
May 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Oct 2021 — May 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Jul 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kyowa Kirin Co., Ltd.
- Kyowa Kirin, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .